Table 2 Incidence rates, hazard ratios, and odds ratios of hand OA progression per treatment group following Cox regression analysis and GEE analysis among those with distal interphalangeal osteoarthritis at baseline (N = 1340)
Exposure | Hand OA progression events | Person-time [years] | IR per 1000 person-years | Crude HR (95% CI) | Adjusted HR (95% CI)a | Crude OR (95% CI) | Adjusted OR (95% CI)a |
|---|---|---|---|---|---|---|---|
Analysis using baseline information only | |||||||
csDMARD | 526 | 3306.0 | 159.1 | Ref (1.00) | Ref (1.00) | NA | NA |
bDMARD | 34 | 244.7 | 138.9 | 0.96 (0.71–1.31) | 1.07 (0.78–1.46) | NA | NA |
Combination | 132 | 886.6 | 148.9 | 1.03 (0.85–1.24) | 1.09 (0.89–1.32) | NA | NA |
Past-use | 8 | 53.8 | 148.7 | 1.24 (0.70–2.19) | 1.15 (0.60–2.20) | NA | NA |
Never-use | 83 | 629.7 | 131.8 | 0.77 (0.61–0.97) | 0.81 (0.63–1.02) | NA | NA |
Time-varying analysis | |||||||
csDMARD | 421 | 2885.7 | 145.9 | Ref (1.00) | Ref (1.00) | Ref (1.00) | Ref (1.00) |
bDMARD | 79 | 391.9 | 201.6 | 1.23 (0.98–1.54) | 1.34 (1.07–1.69) | 1.49 (1.15–1.93) | 1.53 (1.17–2.00) |
TNFi | 67 | 357.6 | 187.4 | 1.16 (0.91–1.48) | 1.26 (0.98–1.62) | 1.36 (1.03–1.79) | 1.41 (1.06–1.88) |
Non-TNFi | 12 | 34.3 | 349.9 | 1.85 (1.18–2.89) | 2.07 (1.35–3.20) | 2.94 (1.50–5.77) | 2.79 (1.41–5.52) |
Combination | 236 | 1378.7 | 171.2 | 1.05 (0.90–1.22) | 1.12 (0.96–1.31) | 1.12 (0.95–1.33) | 1.16 (0.97–1.38) |
TNFi | 210 | 1293.7 | 162.3 | 1.01 (0.86–1.18) | 1.09 (0.92–1.28) | 1.07 (0.90–1.28) | 1.11 (0.93–1.33) |
Non-TNFi | 26 | 85 | 305.9 | 1.54 (1.10–2.15) | 1.56 (1.10–2.23) | 1.75 (1.13–2.73) | 1.77 (1.13–2.77) |
Past-use | 24 | 128.4 | 186.9 | 0.96 (0.64–1.42) | 0.96 (0.66–1.41) | 1.36 (0.87–2.14) | 1.30 (0.83–2.05) |
Never-use | 23 | 335.9 | 68.5 | 0.51 (0.31–0.83) | 0.54 (0.33–0.90) | 0.89 (0.57–1.38) | 0.91 (0.58–1.42) |